Physician profile
Brian Smith
NPI 1538179452
$3,758.79
in general payments reported to CMS, 2019-2025
18 companies · $380 in 2025
The $380 reported for 2025 was more than what 80% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $168 · 2021: $390 · 2022: $610 · 2023: $681 · 2024: $563 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,623.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $925.66 | 2021-2024 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $696.14 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $593.56 | 2019-2023 | |
| Novo Nordisk INC | $454.69 | 2019-2025 | Ozempic, Wegovy |
| Allergan, INC. | $418.84 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $234.67 | 2019-2022 | |
| Lilly USA, LLC | $125.00 | 2024 | Mounjaro |
| Pfizer INC. | $48.61 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.55 | 2019-2022 | |
| Alkermes, INC. | $44.06 | 2019-2023 | Vivitrol |
| Idorsia Pharmaceuticals US INC | $41.70 | 2023 | Quviviq |
| Shire North American Group INC | $29.60 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.08 | 2022 | |
| Genentech USA, INC. | $15.00 | 2020 | |
| Adlon Therapeutics L.P. | $14.82 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $14.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.41 | 2019 | |
| Grifols USA, LLC | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.